Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OCUL logo OCUL
Upturn stock ratingUpturn stock rating
OCUL logo

Ocular Therapeutix Inc (OCUL)

Upturn stock ratingUpturn stock rating
$11.03
Last Close (24-hour delay)
Profit since last BUY30.38%
upturn advisory
Strong Buy
BUY since 25 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: OCUL (4-star) is a STRONG-BUY. BUY since 25 days. Profits (30.38%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $17.92

1 Year Target Price $17.92

Analysts Price Target For last 52 week
$17.92 Target price
52w Low $5.79
Current$11.03
52w High $11.78

Analysis of Past Performance

Type Stock
Historic Profit 171.41%
Avg. Invested days 39
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.76B USD
Price to earnings Ratio -
1Y Target Price 17.92
Price to earnings Ratio -
1Y Target Price 17.92
Volume (30-day avg) 12
Beta 1.41
52 Weeks Range 5.79 - 11.78
Updated Date 07/12/2025
52 Weeks Range 5.79 - 11.78
Updated Date 07/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.11

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -597.47%

Management Effectiveness

Return on Assets (TTM) -27.21%
Return on Equity (TTM) -57.19%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1483619088
Price to Sales(TTM) 29.46
Enterprise Value 1483619088
Price to Sales(TTM) 29.46
Enterprise Value to Revenue 24.87
Enterprise Value to EBITDA -6.06
Shares Outstanding 159300000
Shares Floating 122343790
Shares Outstanding 159300000
Shares Floating 122343790
Percent Insiders 3.82
Percent Institutions 87.01

ai summary icon Upturn AI SWOT

Ocular Therapeutix Inc

stock logo

Company Overview

overview logo History and Background

Ocular Therapeutix, Inc. was founded in 2006. It's a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel platform technology. Significant milestones include the FDA approval and commercialization of DEXTENZAu00ae for post-surgical ocular inflammation and its pipeline of other ophthalmic drug candidates.

business area logo Core Business Areas

  • Commercial Products: DEXTENZAu00ae for the treatment of ocular inflammation and pain following ophthalmic surgery. Also offering ReSureu00ae Sealant, although the revenues from this product is lower.
  • Pipeline Development: Developing a portfolio of sustained-release drug candidates for various ophthalmic conditions, including glaucoma, dry eye disease, and retinal diseases.

leadership logo Leadership and Structure

The leadership team consists of key executives such as the CEO, CFO, and Chief Medical Officer. The organizational structure includes departments for research and development, clinical operations, commercialization, and finance.

Top Products and Market Share

overview logo Key Offerings

  • DEXTENZA: DEXTENZAu00ae is a corticosteroid insert placed in the punctum (tear duct) of the eye following cataract surgery to treat post-operative inflammation and pain for up to 30 days. It aims to improve patient compliance and reduce the need for frequent eye drops. Market share data is growing but still a smaller percentage. Competitors include generic steroid eye drops and other branded eye drops like PROLENSAu00ae (bromfenac ophthalmic solution) 0.07% and ILEVROu00ae (nepafenac ophthalmic suspension) 0.3%.
  • ReSure Sealant: ReSure Sealant is a hydrogel sealant applied to corneal incisions to prevent wound leaks following cataract surgery. Revenues from ReSure are lower than Dextenza. Main competitors are other methods of wound closure like sutures.

Market Dynamics

industry overview logo Industry Overview

The ophthalmic pharmaceutical market is characterized by increasing prevalence of eye diseases, an aging population, and technological advancements in treatment options. Key areas of focus include treatments for glaucoma, dry eye, macular degeneration, and post-operative care.

Positioning

Ocular Therapeutix is positioned as an innovator in sustained-release ophthalmic drug delivery. Its bioresorbable hydrogel technology offers a competitive advantage by providing controlled and prolonged drug release, potentially improving patient adherence and outcomes.

Total Addressable Market (TAM)

The global ophthalmic drug market is estimated to be substantial, with some estimates projecting it to exceed $40 billion in the coming years. Ocular Therapeutix is positioned to capture a segment of this market by addressing unmet needs in post-operative care and chronic eye diseases.

Upturn SWOT Analysis

Strengths

  • Proprietary bioresorbable hydrogel technology
  • FDA-approved product (DEXTENZAu00ae)
  • Strong intellectual property portfolio
  • Potential for improved patient compliance with sustained-release delivery

Weaknesses

  • Limited commercial infrastructure compared to larger pharmaceutical companies
  • Reliance on a single key product (DEXTENZAu00ae) for revenue
  • Ongoing need for capital to fund research and development
  • Manufacturing complexities associated with bioresorbable hydrogel

Opportunities

  • Expansion of DEXTENZAu00ae label to other indications
  • Development of new sustained-release therapies for chronic eye diseases
  • Strategic partnerships with larger pharmaceutical companies
  • Increasing awareness of the benefits of sustained-release drug delivery

Threats

  • Competition from generic and branded ophthalmic drugs
  • Regulatory hurdles and clinical trial risks
  • Pricing pressures from healthcare payers
  • Potential for product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • ALC (Alcon)
  • JNJ (Johnson & Johnson)
  • VRX (Bausch Health)

Competitive Landscape

Ocular Therapeutix's advantage lies in its sustained-release technology. Its disadvantage is the smaller size and relative lack of experience compared to larger, established competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the launch and increasing adoption of DEXTENZAu00ae.

Future Projections: Future growth is expected to depend on the expansion of DEXTENZAu00ae's label, the development of new pipeline products, and strategic partnerships.

Recent Initiatives: Recent initiatives include clinical trials for new indications, strategic collaborations, and efforts to expand market access for DEXTENZAu00ae.

Summary

Ocular Therapeutix is a biopharmaceutical company with innovative technology and an FDA-approved product, DEXTENZA. The company has the potential for growth through pipeline development and market expansion. However, it faces challenges related to commercialization, competition, and funding. Investors should closely monitor clinical trial results, regulatory developments, and financial performance to assess the company's prospects. The long-term success hinges on its ability to translate its innovative technology into commercially successful products and navigate the competitive landscape.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings (10-K, 10-Q)
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market data and projections are subject to change and may not be accurate. Investors should conduct their own due diligence before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ocular Therapeutix Inc

Exchange NASDAQ
Headquaters Bedford, MA, United States
IPO Launch date 2014-07-25
Executive Chairman, President & CEO Dr. Pravin U. Dugel M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 274
Full time employees 274

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.